中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 9
Sep.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(9): 1970-1974

Effect of intraoperative Viatorr stent implantation for shunting of blood flow in the left or right branch of the portal vein and its effect on clinical outcome in patients with cirrhotic portal hypertension undergoing transjugular intrahepatic portosystemic shunt

DOI: 10.3969/j.issn.1001-5256.2020.09.012

  • Department of Gastroenterology, The General Hospital of Western Theater Command

Research funding:

 

  • Published Date: 2020-09-20
    Abstract

  • Objective To investigate the effect of intraoperative Viatorr stent implantation for shunting of blood flow in the left or right branch of the portal vein on the clinical outcome of patients with cirrhotic portal hypertension undergoing transjugular intrahepatic portosystemic shunt( TIPS). Methods A retrospective analysis was performed for the clinical data of 120 patients with cirrhotic portal hypertension who underwent TIPS in The General Hospital of Western Theater Command from March 2016 to December 2019,and according to the target position of portal vein puncture determined by intraoperative angiography,the patients were divided into left branch group and right branch group.The two groups were compared in terms of the incidence rates of postoperative recurrence and bleeding,stent dysfunction,and hepatic encephalopathy( HE) and survival. The t-test was used for comparison of continuous data between two groups,and the chi-square test was used for comparison of categorical data between two groups. The Kaplan-Meier curve was used to calculate rebleeding rate,stent patency rate,incidence rate of HE,and survival rate. Results The surgical success rate was 100% for all 120 patients,with a short-term hemostasis rate of100%. Among the 120 patients,52 underwent shunting of the left branch of the portal vein and 68 underwent shunting of the right branch.There was a significant reduction in portal venous pressure after surgery( 9. 98 ± 2. 84 mm Hg vs 24. 72 ± 5. 11 mm Hg,t = 37. 76,P < 0. 01).The cumulative rebleeding rates at 12 and 24 months after surgery were 3. 2% and 11. 0%,respectively,and the cumulative incidence rates of HE at 3,6,12,and 24 months after surgery were 10. 8%,13. 6%,21. 2%,and 24. 5%,respectively. Among the 29 patients who experienced HE,23 had gradeⅠ-ⅡHE and 6 had grade Ⅲ HE. The cumulative incidence rates of stent dysfunction at 12 and 24 months after surgery were 7. 1% and 21. 4%,respectively. The cumulative survival rates at 12 and 24 months after surgery were 92. 0% and 86. 5%,respectively.As for comparison of the left branch group and the right branch group,there were no significant differences in postoperative stent patency rate,rebleeding rate,incidence rate of HE,and survival rate( all P < 0. 05). Conclusion TIPS is a safe and effective method for the treatment of cirrhotic portal hypertension,and intraoperative Viatorr stent implantation,no matter for establishing the shunt of the left or right branch of the portal vein,will not affect the clinical outcome of patients.

     

    • FullText(HTML)
    • References(22)
  • [1] MALK J,HOLAJ R,KRUPICˇKOVZ,et al. Arteriovenous fistula after femoral artery puncture leading to pulmonary edema:The role of ultrasonography[J]. Prague Med Rep,2012,113(1):49-52.
    [2] CASTILLO-SANG M,TSANG AW,ALMAROOF B,et al. Femoral artery complications after cardiac catheterization:A study of patient profile[J]. Ann Vasc Surg,2010,24(3):328-335.
    [3] QIN JP,TANG W,TANG SH,et al. Modifiedtransjugular intrahepatic portosystemic shunt in the treatment of portal hypertemion of liver cirrhosis[J]. Chin J Dig,2014,34(1):33-36.(in Chinese)秦建平，唐文，汤善宏，等．改良经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压症[J]．中华消化学杂志，2014,34(1):33-36.
    [4] YAO X,ZHOU H,TANG SH,et al. Stent dysfunction after transjugular intrahepatic portosystemic stent:Causes and countermeasures[J]. J Clin Hepatol,2019,35(5):1052-1056.(in Chinese)姚欣，周昊，汤善宏，等．经颈静脉肝内门体分流术后支架功能障碍的原因分析及处理策略[J]．临床肝胆病杂志，2019,35(5):1052-1056.
    [5] Interventional Group,Chinese Society of Radiology,Chinese Medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol,2017,33(7):1218-1228.(in Chinese)中华医学会放射学分会介入学组．经颈静脉肝内门体分流术专家共识[J]．临床肝胆病杂志，2017,33(7):1218-1228.
    [6] The Chinese College of Interventionalists. CCI clinical practice guidelines:Management of TIPS for portal hypertension(2019edition)[J]. J Clin Hepatol,2019,35(12):2694-2699.(in Chinese)中国医师协会介入医师分会．中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2694-2699.
    [7] Group of Gastrointestinal Intervention,Chinese Society of Gastroenterology, Chinese Medical Association. Consensus on transjugular intrahepatic portosystemic shunt for treatment of cirrhotic portal hypertension[J]. J Clin Hepatol,2014,30(3):210-213.(in Chinese)中华医学会消化病学分会消化介入学组．经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压共识意见[J]．临床肝胆病杂志，2014,30(3):210-213.
    [8] THOMAS DB,HASKAL ZJ. The role of transjugular intrahepatic portosystemic shunt(TIPS)in the management of portal hypertension:Update 2009[J]. Hepatology,2010,51(1):386-400.
    [9] QIN JP,TANG SH,JIANG MD,et al. Contrast enhanced computed tomography and reconstruction of hepatic vascular system for transjugular intrahepatic portal systemic shunt puncture path planning[J]. World J Gastroenterol,2015,21(32):9623-9629.
    [10] TANG SH,QIN JP,JIANG MD,et al. The agreement and clinical value of hepatic vein pressure gradient and portal vein pressure in patients with portal hypertension[J]. Chin J Hepatol,2015,23(5):354-357.(in Chinese)汤善宏，秦建平，蒋明德，等．门静脉高压患者肝静脉压力梯度与门静脉压相关性及其临床价值[J]．中华肝脏病杂志，2015,23(5):354-357.
    [11] TRIPATHI D,STANLEY AJ,HAYES PC,et al. U. K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut,2015,64(11):1680-1704.
    [12] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol,2017,10(33):1847-1863.(in Chinese)中华医学会肝病学分会．肝硬化腹水及相关并发症的诊疗指南[J]．临床肝胆病杂志，2017,10(33):1847-1863.
    [13] BERCU ZL,FISCHMAN AM,KIM E,et al. TIPS for refractory ascites:A 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts[J]. AJR Am J Roentgenol,2015,204(3):654-661.
    [14] CHU JG,SUN XL,PIAO LS,et al. Portosystemic shunt via left branch of portal vein for the prevention of encephalopathy following transjugular intrahepatic portosystemic shunt[J]. Chin J Hepatol,2002,10(6):437-440.(in Chinese)褚建国，孙晓丽，朴龙松，等．门静脉左支分流降低术后肝性脑病的临床研究[J]．中华肝脏病杂志，2002,10(6):437-440.
    [15] MOGICATO G,VAUTAVERS G,MEYNAUD-COLLARD P,et al. Blood flows in tributaries of the portal vein:Anatomical andangiographic studies in normal beagle dogs[J]. Anat Histol Embryol,2015,44(6):460-467.
    [16] LJUBICIC N,DUVNJAK M,ROTKVIC I,et al. Influence of the degree of liver failure on portal blood flow in patientswith liver cirrhosis[J]. Scand J Gastroenterol,1990,25(4):395-400.
    [17] QIN JP,JIANG MD,TANG W,et al. Clinical effects and complications of TIPS for portal hypertension due to cirrhosis:A single center[J]. World J Gastroenter,2013,19(44):8085-8092.
    [18] CHARON JP,ALAEDDIN FH,PIMPALWAR SA,et al. Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation[J]. J Vasc Interv Radiol,2004,15(11):1219-1230.
    [19] VIGNALI C,BARGELLINI I,GROSSO M,et al. TIPS with expanded polytetrafluoroethylene-covered stent:Results of an Italian multicenter study[J]. AJR Am J Roentgenol,2005,185(2):472-480.
    [20] ANGELONI S,MERLI M,SALVATORI FM,et al. Polytetrafluoroethylene-covered stent grafts for TIPS procedure:1-year patency and clinical results[J]. Am J Gastroenterol,2004,99(2):280-285.
    [21] DARCY M. Evaluation and management of transjugularintra hepatic portosystemic shunts[J]. Am J Roentgenol,2012,199(4):730-736.
    [22] SAAD WE,DARWISH WM,DAVIES MG,et al. Stent-grafts for transjugular intrahepatic portosystemic shunt creation:Specialized TIPS stent-graft versus generic stent-graft/bare stent combination[J]. J Vasc Interv Radiol,2010,21(10):1512-1520.
    • Relative Articles

  • Relative Articles

    [1]Jinqiu YANG, Wenxia ZHAO, Cheng ZHOU, Tong LIU. Risk factors for the development of advanced liver fibrosis in nonalcoholic fatty liver disease and establishment of a nomogram model[J]. Journal of Clinical Hepatology, 2024, 40(8): 1579-1584. doi: 10.12449/JCH240812
    [2]Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914
    [3]Decai KONG, Xiaojing ZHANG, Yangguang YUN, Haoyu DUAN, Junfeng YE. Risk factors for biliary stricture and prognosis after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(11): 2253-2259. doi: 10.12449/JCH241119
    [4]Mingqiang ZHU, Dashuai YANG, Junpeng PEI, Xiangyun XIONG, Yang SU, Youming DING. Analysis of influencing factors on biliary complications after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2023, 39(7): 1627-1632. doi: 10.3969/j.issn.1001-5256.2023.07.017
    [5]Sufang LU, Rui HUANG, Hongli ZHAO, Dandan WANG, Yuzhen DING, Hong ZHOU. Value of a risk assessment model in predicting venous thromboembolism in patients with liver failure after artificial liver support therapy[J]. Journal of Clinical Hepatology, 2023, 39(3): 613-619. doi: 10.3969/j.issn.1001-5256.2023.03.019
    [6]Bingbing ZHU, Jinxiang YANG, Qun ZHANG, Fangyuan GAO, Xianbo WANG. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2022, 38(7): 1561-1565. doi: 10.3969/j.issn.1001-5256.2022.07.019
    [7]Perioperative Management Group, Chinese Society of Organ Transplantation, Chinese Medical Association. Expert consensus on perioperative vascular complications for liver transplantation(2021)[J]. Journal of Clinical Hepatology, 2021, 37(9): 2054-2057. doi: 10.3969/j.issn.1001-5256.2021.09.010
    [8]Bing GUO, Mingquan PANG, Xiaolei XU, Junwei HAN, Haijiu WANG. Establishment and evaluation of a nomogram for predicting post-hepatectomy complications in two types of hepatic echinococcosis[J]. Journal of Clinical Hepatology, 2021, 37(11): 2626-2631. doi: 10.3969/j.issn.1001-5256.2021.11.027
    [9]Yun ZHAO, Lijin ZHAO. Research advances in the risk factors for infection after liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(8): 1957-1962. doi: 10.3969/j.issn.1001-5256.2021.08.046
    [10]Mingwei LI, Jian GAO, Xiangwei ZHAI, Xiangjun QIAN, Xiajie WEN, Mingjie YAO, Zhaojun DUAN, Erjiang ZHAO, Ling ZHANG, Fengmin LU. Construction and analysis of a predictive model for posthepatectomy recurrence in patients with hepatocellular carcinoma based on preoperative CXCL13 measurement[J]. Journal of Clinical Hepatology, 2021, 37(4): 823-828. doi: 10.3969/j.issn.1001-5256.2021.04.020
    [11]Wang Han, Zuo XiangRong, Cao Quan. Predictive factors and interventions for prolonged mechanical ventilation after liver transplantation[J]. Journal of Clinical Hepatology, 2020, 36(7): 1658-1662. doi: 10.3969/j.issn.1001-5256.2020.07.047
    [12]Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
    [13]Zheng WeiPing, Shen ZhongYang. Risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma and related control strategies[J]. Journal of Clinical Hepatology, 2019, 35(11): 2391-2395. doi: 10.3969/j.issn.1001-5256.2019.11.003
    [14]Chen Long, Li Yue. The risk factors and prediction systems for posthepatectomy complications[J]. Journal of Clinical Hepatology, 2019, 35(1): 217-221. doi: 10.3969/j.issn.1001-5256.2019.01.048
    [15]Jie EnBo, Xuan FengHui, Sun XiaoDong, Sun DaWei, Lu: GuoYue. An analysis of risk factors for early complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(6): 1282-1288. doi: 10.3969/j.issn.1001-5256.2018.06.030
    [16]Zhang YinTao, Meng JinYing, Guo ChunGuang, Wang Hua. Risk factors for biliary complications after common bile duct exploration combined with primary suture[J]. Journal of Clinical Hepatology, 2017, 33(2): 304-307. doi: 10.3969/j.issn.1001-5256.2017.02.021
    [17]Wang XinWei, Zhao ZongGang. Risk factors for infectious complications after hepatectomy in patients with intrahepatic bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(9): 1754-1757. doi: 10.3969/j.issn.1001-5256.2017.09.025
    [18]Wang MingYue, Lu ZhiYan. Imaging evaluation of complications after liver transplantation[J]. Journal of Clinical Hepatology, 2016, 32(12): 2295-2299. doi: 10.3969/j.issn.1001-5256.2016.12.013
    [19]Lu: GuoYue. Risk factors for biliary complications after liver transplantation from donation after cardiac death[J]. Journal of Clinical Hepatology, 2015, 31(12): 2027-2030. doi: 10.3969/j.issn.1001-5256.2015.12.009
    [20]Chen Man, Zhang Xia. Research advances in molecular prediction of recurrence and metastasis of primary liver cancer after liver transplantation[J]. Journal of Clinical Hepatology, 2014, 30(12): 1361-1365. doi: 10.3969/j.issn.1001-5256.2014.12.032
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(4)

    1. 李正优，李荷，周俊. 预见性护理结合舒适护理干预在肝移植术后患者中的应用. 西藏医药. 2024(06): 123-125 .
    2. 李珊珊，王媛，高春辉. 早期下床活动对肝移植术后患者胃肠功能及下肢血流的影响. 国际移植与血液净化杂志. 2023(01): 41-44 .
    3. 张欣悦，王海刚，王昊，杨传伟. 他克莫司治疗1例肝移植术后患者的药学监护. 中国医药导报. 2023(14): 183-187 .
    4. 种庚，彭晓春，吴若林，赵红川，邵敏. 成人肝移植术后早期严重并发症相关危险因素分析. 肝胆外科杂志. 2022(06): 454-459 .

    Other cited types(0)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0402.557.51012.515
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 29.9 %FULLTEXT: 29.9 %META: 63.7 %META: 63.7 %PDF: 6.4 %PDF: 6.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.8 %其他: 5.8 %其他: 1.5 %其他: 1.5 %Greece: 0.4 %Greece: 0.4 %India: 0.3 %India: 0.3 %Russian Federation: 0.1 %Russian Federation: 0.1 %United States: 0.4 %United States: 0.4 %[]: 0.5 %[]: 0.5 %上海: 3.3 %上海: 3.3 %东莞: 0.2 %东莞: 0.2 %中山: 0.1 %中山: 0.1 %乌鲁木齐: 0.4 %乌鲁木齐: 0.4 %保定: 0.2 %保定: 0.2 %包头: 0.1 %包头: 0.1 %北京: 4.3 %北京: 4.3 %十堰: 0.1 %十堰: 0.1 %南京: 0.6 %南京: 0.6 %南充: 0.4 %南充: 0.4 %南宁: 0.3 %南宁: 0.3 %南阳: 0.1 %南阳: 0.1 %卡纳塔克: 0.5 %卡纳塔克: 0.5 %印度中央邦: 0.3 %印度中央邦: 0.3 %厦门: 0.2 %厦门: 0.2 %台州: 0.4 %台州: 0.4 %合肥: 0.1 %合肥: 0.1 %吉林: 0.4 %吉林: 0.4 %哈密: 0.1 %哈密: 0.1 %哥伦布: 0.1 %哥伦布: 0.1 %大连: 1.4 %大连: 1.4 %天津: 1.7 %天津: 1.7 %宁波: 0.6 %宁波: 0.6 %安康: 0.4 %安康: 0.4 %宜昌: 0.1 %宜昌: 0.1 %密蘇里城: 0.2 %密蘇里城: 0.2 %常德: 0.1 %常德: 0.1 %广州: 2.6 %广州: 2.6 %弗吉尼亚州: 0.1 %弗吉尼亚州: 0.1 %张家口: 2.2 %张家口: 2.2 %意法半: 0.1 %意法半: 0.1 %成都: 0.8 %成都: 0.8 %新乡: 0.2 %新乡: 0.2 %新加坡: 0.1 %新加坡: 0.1 %昆明: 1.1 %昆明: 1.1 %晋城: 0.2 %晋城: 0.2 %杭州: 2.0 %杭州: 2.0 %桂林: 0.3 %桂林: 0.3 %武汉: 0.7 %武汉: 0.7 %江门: 0.1 %江门: 0.1 %济南: 0.4 %济南: 0.4 %海得拉巴: 0.2 %海得拉巴: 0.2 %深圳: 0.2 %深圳: 0.2 %温州: 0.2 %温州: 0.2 %湖州: 0.5 %湖州: 0.5 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.2 %漯河: 0.2 %濮阳: 0.1 %濮阳: 0.1 %烟台: 0.1 %烟台: 0.1 %眉山: 0.1 %眉山: 0.1 %石家庄: 0.3 %石家庄: 0.3 %福州: 0.2 %福州: 0.2 %绍兴: 0.1 %绍兴: 0.1 %耶拿: 0.2 %耶拿: 0.2 %芒廷维尤: 38.8 %芒廷维尤: 38.8 %芝加哥: 0.2 %芝加哥: 0.2 %莫斯科: 1.5 %莫斯科: 1.5 %衡水: 0.3 %衡水: 0.3 %衢州: 0.2 %衢州: 0.2 %西宁: 14.4 %西宁: 14.4 %西安: 0.3 %西安: 0.3 %贵阳: 0.1 %贵阳: 0.1 %赣州: 0.4 %赣州: 0.4 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.5 %运城: 1.5 %邯郸: 0.1 %邯郸: 0.1 %重庆: 0.4 %重庆: 0.4 %长春: 0.9 %长春: 0.9 %长沙: 0.9 %长沙: 0.9 %香港: 0.2 %香港: 0.2 %其他其他GreeceIndiaRussian FederationUnited States[]上海东莞中山乌鲁木齐保定包头北京十堰南京南充南宁南阳卡纳塔克印度中央邦厦门台州合肥吉林哈密哥伦布大连天津宁波安康宜昌密蘇里城常德广州弗吉尼亚州张家口意法半成都新乡新加坡昆明晋城杭州桂林武汉江门济南海得拉巴深圳温州湖州湘潭漯河濮阳烟台眉山石家庄福州绍兴耶拿芒廷维尤芝加哥莫斯科衡水衢州西宁西安贵阳赣州赤峰运城邯郸重庆长春长沙香港

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1421) PDF downloads(130) Cited by(4)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2389]YesterdayPV[5285]TodayIP[1972]TodayPV[4352]Online[53]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return